Back to search
Esophageal Squamous Cell Carcinoma (ESCC)
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Esophageal Squamous Cell Carcinoma (ESCC) trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Esophageal Squamous Cell Carcinoma (ESCC) trials you may qualify forThis is a prospective, randomized, phase II clinical study in patients with unresectable stage III-IVA esophageal squamous cell carcinoma (ESCC). Eligible patie…
The primary objective is to compare PD-1 inhibitor combined with preoperative chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy follow…
The goal of this clinical trial is to assess the percentage of patients alive at 6 months in elderly patients, not eligible to an platinum-based chemotherapy, b…
This study is designed to assess the efficacy and safety of QLC5508 in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESC…
This is a single-arm, single-center, open-label, observational clinical study. A total of 30 patients with initially unresectable locally advanced esophageal sq…
This study is an open-label, multi-center phase II clinical trial aimed to evaluat the safety and preliminary efficacy of JS212 combination therapy in patients…
Prospectively collect the pathological records of ESCC patients, and analyse the infiltration pattern of ESCC.
Taxane-based agents are widely used in the treatment of esophageal squamous cell carcinoma (ESCC). Among these, nab-paclitaxel (albumin-bound paclitaxel) and pa…
The purpose of this study is to assess the efficacy and safety of QL1706 combined with nab-paclitaxel and cisplatin in first-line therapy for patients with adva…